NeoGenomics (NEO) Q3 2026 Earnings Call Transcript

NeoGenomics reported Q3 revenue of $209 million, up 11% year over year, with NGS revenue growth of 29%, adjusted gross margin expanding 310 basis points to 48.6%, and adjusted EBITDA rising 53% to $19 million. The company raised FY2026 revenue guidance to $807–$809 million from $802–$806 million and adjusted EBITDA guidance to approximately $60 million from $56–$58 million. Growth and margin momentum are partly offset by nonclinical revenue declining 10%, a $10 million DOJ settlement payment, and potential gross-margin pressure from unreimbursed RaDaR ST testing; Warren Stone is set to become CEO on Jan. 4, 2027.

Analysis

The earnings quality is better than headline growth, but less uniform: NGS mix and payer pricing are lifting unit economics while total test volumes remain modest. The key question is whether panel growth reflects durable share gains against Guardant Health, Tempus AI, and large reference labs, or mostly higher value per test; management did not quantify win rates or same-customer growth. Community workflow integration is a plausible defense, but not yet proof of sustained share capture.

Near term, the market may capitalize the raised outlook and margin expansion. Over 1–3 months, the more important tests are Q4 delivery, XiFin receivables normalization, and whether RaDaR orders convert into reimbursed recurring use. Unreimbursed MRD testing creates a launch-stage margin drag; approvals and physician trialing alone do not establish attractive unit economics. Over 6–18 months, NovaSeq X efficiency and broader coverage could support margins and growth, but platform transition and sales-force spending precede much of the payoff. The CEO handoff appears strategically continuous, though execution and 2027 budget ownership remain catalysts.

Contrarian risk: investors may extrapolate the 11% AUP increase, although some is mix and pricing rather than broad volume acceleration. Conversely, the market may underweight the option value of NGS penetration in community oncology. No valuation or share-price context is supplied, so avoid chasing an earnings-day move; falsification would be renewed gross-margin contraction, stalled NGS panel volumes, or receivables failing to normalize by early 2027.

Key Decisions for Investors

• NEO: Prefer a staged long on post-earnings consolidation rather than chasing an immediate gap. Reassess after Q4 results; require continued large-panel volume growth and stable/improving adjusted gross margin. Thesis weakens if either reverses materially.
• Treat RaDaR ST as a catalyst watch, not yet a standalone earnings driver. Track MolDX decisions, commercial-plan implementation, in-indication repeat ordering, and reimbursed share; expanding orders without reimbursement would worsen the margin profile.
• Monitor cash conversion separately from adjusted EBITDA: verify receivables and collections trend toward normalization by early 2027. A persistent working-capital build would challenge the quality of reported operating leverage.
• For relative diligence, compare NEO’s panel growth and community-account retention with Guardant Health and Tempus AI; do not assume share gains until the company provides comparable win-rate or customer-level evidence.